Use of the “SMITEST” PSA card to identify the presence of prostate-specific antigen in semen and male urine

Sato, Itaru; Sagi, Morihisa; Ishiwari, Atsuya; Nishijima, Hironori; Ito, Emi; Mukai, Toshiji

doi:10.1016/s0379-0738(02)00111-1

Cited by 48 publications

(42 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These proteins are well known to play a role in spontaneous semen coagulation after ejaculation and Sg-I inhibits sperm motility [9,17]. Recently, Sato et al [18,19] reported Sg to be a more suitable marker for semen identification than prostatespecific antigen (PSA) and subsequently, a sensitive membrane-based Sg test was developed and made commercially available for forensic use in Japan in 2004. We tested for the presence of Sg in forensic samples using this new immunochromatography method.…”

Section: Introductionmentioning

confidence: 99%

Applicability of Nanotrap Sg as a semen detection kit before male-specific DNA profiling in sexual assaults

Sato

Barni²,

Yoshiike

et al. 2006

Int J Legal Med

Self Cite

View full text Add to dashboard Cite

A commercially available semen detection kit, Nanotrap Sg, which employs a one-step detection test based on immunochromatographic assay for the semenogelin protein, was evaluated for profiling male-specific DNA in sexual assault casework samples. While semen diluted with phosphate-buffered saline held and kept at 4 degrees C for 1 week showed a relatively strong signal intensity with Nanotrap Sg, the signal intensity was decreased by dilution after storage at 4 degrees C or freezing and thawing repeated more than three times. The reproducibility of Nanotrap Sg was tested on a total of 174 sexual assault casework samples from three forensic laboratories using intra- and interassay and no variation was observed in the semenogelin (Sg) signal. The positive signal ratio was 12.6% higher for prostate-specific antigen immunochromatographic membrane tests than Nanotrap Sg. Although spermatozoa were not confirmed in 61 (35%) out of 174 samples, Sg-positive signals could be detected from 41 (67%) of the 61 samples. Female genetic profiles could be observed in 95% of the samples, which tested negative for Sg on the Nanotrap Sg test, but no male genetic profiles could be observed. These results suggest that Nanotrap Sg can positively identify samples containing male DNA even in the absence of detectable intact spermatozoa. Further, Sg-positive signals identified samples for which male-specific DNA profiling could be performed, even if no sperm could be detected from the sample. The potential of Nanotrap Sg for identifying forensic samples with male-specific DNA was clearly demonstrated.

show abstract

Section: Introductionmentioning

confidence: 99%

Applicability of Nanotrap Sg as a semen detection kit before male-specific DNA profiling in sexual assaults

Sato

Barni²,

Yoshiike

et al. 2006

Int J Legal Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Это при том, что средняя частота встречаемости онкологических пациентов в Рос-сии составляет 26,8 случаев на 100 000 населения [4], из которых на долю женщин приходится ~ 75 %, что грозит значительным риском ошибок определения пола в тех образцах, где невозможно определить ДНК-профиль. Кроме того, PSA присутствует в разных тканях и может встречаться, например, в крови мужчин, перенесших вазэктомию [5], а также в моче [6].…”

Section: определение семенной жидкостиunclassified

Tissue Typing by Means of PCR and Capillary Electrophoresis: New Aspects, Reality and Issues

Bavykin¹

2017

Russian Journal of Forensic Medicine

View full text Add to dashboard Cite

ООО «Ниармедик плюс», Москва Аннотация: Целью текущего обзора является раскрытие новых перспектив для РНК-и ДНК-анализа в ру-тинной практике судебной биологии. В обзоре рассмотрены современные тканевые маркеры, основанные на матричных РНК (мРНК), методы их тестирования и подходы для совмещения РНК-анализа со стандартными протоколами исследования судебного материала. Исходя из практического опыта зарубежных исследователей, новые маркеры вполне совместимы с класси-ческими протоколами, включая использование методов ПЦР и капиллярного электрофореза, и могут быть применены после постановки иммунологических тестов, что усиливает чувствительность и не требует прин-ципиального отказа от их использования. На сегодняшний день сформированы относительно готовые мультиплексные тканевые наборы, подготовлен-ные для коммерческих реализаций в скором будущем. Популяционное генетическое разнообразие в экспрес-сии генов определяет возможность разработки отечественных панелей мРНК-маркеров на базе существующих зарубежных панелей. Ключевые слова: типирование тканей, тканевые мРНК-маркеры TISSUE TYPING BY MEANS OF PCR AND CAPILLARY ELECTROPHORESIS: NEW ASPECTS, REALITY AND ISSUESBavykin A.S. Abstract: «When the DNA is not enough» -an issue that becoming popular among forensic biologists [1]. The reasons for that are methods of tissue typing, that have limited accuracy and gradually becoming obsolete. The purpose of this review is to discuss the integration of new mRNA markers to the routine genetic forensic practice. The review discusses possibilities of utilizing the developed mRNA biomarkers for tissue typing as well as the approaches of combining gene expression analyses with standard sample workflow in forensic and criminal laboratories. Based on data obtained by the foreign researches, new mRNA markers are quite compatible with classical protocols, including PCR and capillary electrophoresis, increase the specificity of immunological methods and do not require rejection of their use. In the near future we can expect commercially developed tissue specific and multiplex assays at markets abroad. Although population diversity of genetic expression does not allow to create a universal multiplex panel, nevertheless the existing tissue mRNA panel can be enriched by the national features.

show abstract

“…value of TPSA between prostate hyperplasia and cancer is 4 ng/mL. 14 Several detection kits for TPSA, based on immunochromatography, are commercially available 15,16 and mostly target 4 ng/mL as the sensitivity level. A lower cut-off value for younger men (< 59 years old) 17 is required in order avoid risking under diagnosis at an early treatable stage.…”

Section: Application Of Depletion Protocol To Detection Of Prostate Smentioning

confidence: 99%

A Rapid Sample Pretreatment Protocol: Improved Sensitivity in the Detection of a Low-abundant Serum Biomarker for Prostate Cancer

Vestergaard

Tamiya

2007

ANAL. SCI.

View full text Add to dashboard Cite

The detection of small and low abundant biomarkers in clinical samples remains a challenge, mainly due to the presence of high-abundant proteins, such as albumin (HSA) and immunoglobulin G (IgG), accounting for at least 65% of plasma proteins. 1 The depletion of these proteins could facilitate biomarker discovery and detection. Depletion should aim to provide the selective removal of high-abundant proteins, and concentrate components of low abundance. Commercially available methods for IgG and HSA depletion have enabled the visualization of new protein signals, the identification of gene products and improved detection of low-abundant proteins. [2][3][4] Most of the methods utilize either antibody-or dye-based resins, 3,5 molecular size filtration, organic solvents, and ammonium sulfate precipitation, as well as reverse phase and ion exchange chromatography. 5,6 Also available are resins cross-linked with proteins A and G, and their recombinants for IgG removal. 3,7 Antibody-based resins display higher specificity and efficiency, 4,8 but are more expensive than the dye-based resins, limiting their usage. Commercially available pre-packed columns lack the flexibility to accommodate issues pertaining to sample size, for example. In addition, some rely on use of pumps and other equipment to operate smoothly, 2,3 thus limiting their use in many health centers. Most studies on IgG/HSA depletion have focused on the detection of lowabundant proteins using electrophoresis and mass spectrometry.2,3,9 As far as we are aware, the effects of depletion on point-of-care-testing (POCT) immunochromatography membrane-based assays is yet to be reported. Further, an evaluation of the potential benefits of HSA depletion over IgG, and vice versa has received very little attention to date.In this report, we present (a) a versatile method for HSA and IgG depletion from quality control (QC) and human serum samples, (b) assess the effect of depletion on human chorionic gonadotropin (HCG) and prostate specific antigen (PSA) using immunochromatography test strips (ICTS), and (c) evaluate the effects of HSA depletion compared to that of IgG on HCG and PSA detection. We employed a dye-based removal of HSA using Cibacron Blue 3G-A Sepharose (SB). SB has a strong affinity towards HSA. 10 For the removal of IgG, we exploited the high affinity between the Fc region of antibodies and protein G using sepharose beads cross-linked with protein G (S-PG). 7 Experimental MaterialsSB and S-PG were purchased from GE Healthcare BioSciences AB (Uppsala, Sweden). Handee TM spin columns (500 μL) and IgG specific kit (Easy-Titre ® IgG assay kit) were purchased from Pierce (IL, USA). HSA blue fluorescent assay kit was from Active Motif Japan (Tokyo, Japan). Prostate specific antigen (PSA) was obtained from Chemicon International (Temecula, CA, USA). Unless otherwise stated, all other reagents were from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All solutions were prepared and diluted using ultra-pure water (18.3 MΩ cm -1 ) from the Millipore Milli-Q ...

show abstract

Use of the “SMITEST” PSA card to identify the presence of prostate-specific antigen in semen and male urine

Cited by 48 publications

References 11 publications

Applicability of Nanotrap Sg as a semen detection kit before male-specific DNA profiling in sexual assaults

Applicability of Nanotrap Sg as a semen detection kit before male-specific DNA profiling in sexual assaults

Tissue Typing by Means of PCR and Capillary Electrophoresis: New Aspects, Reality and Issues

A Rapid Sample Pretreatment Protocol: Improved Sensitivity in the Detection of a Low-abundant Serum Biomarker for Prostate Cancer

Contact Info

Product

Resources

About